✔ 100% Authentic Product
👁️ Currently Viewing 142
Zoclast 4mg/5ml Infusion
Zoledronic acid is a nitrogen-containing bisphosphonate that selectively inhibits osteoclast-mediated bone resorption. Its high affinity for mineralized bone allows rapid uptake following intravenous administration.
The principal molecular target in osteoclasts is farnesyl pyrophosphate synthase, an enzyme essential for osteoclast function and survival.
Clinical studies in tumor-induced hypercalcemia demonstrate significant reductions in serum and urinary calcium levels. Beyond its anti-resorptive effect, zoledronic acid exhibits anti-tumor, anti-angiogenic, analgesic, cytostatic, and pro-apoptotic activities, and may act synergistically with other anticancer agents.
Zoledronic acid is not metabolized, does not accumulate in plasma with repeated dosing every 28 days, and is excreted unchanged via the kidneys.
Discount
Price: ৳ 6,240
MRP:
৳
6500
4%
Off
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Cash on Delivery - All over Bangladesh
Regular Delivery - 12-24 Hours, Dhaka City* Charge Tk.39-59- Regular Delivery - 24-48 Hours, Other Cities* Charge Tk.99-110
ফ্রি ডেলিভারিঃ - ৯৯৯ টাকা+ অর্ডারে, ঢাকা
শহরে- ফ্রি ডেলিভারিঃ - ২৯৯৯ টাকা+ অর্ডারে, ঢাকার
বাহিরে
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
- Cash on Delivery - All over Bangladesh
- Regular Delivery - 12-24 Hours, Dhaka City* Charge Tk.39-59
- Regular Delivery - 24-48 Hours, Other Cities* Charge Tk.99-110
- ফ্রি ডেলিভারিঃ - ৯৯৯ টাকা+ অর্ডারে, ঢাকা
শহরে
- ফ্রি ডেলিভারিঃ - ২৯৯৯ টাকা+ অর্ডারে, ঢাকার
বাহিরে
✅ Description:
Zoclast is indicated for the management and prevention of bone-related disorders, including:
- Hypercalcaemia of malignancy
- Bone metastases associated with solid tumors
- Osteolytic lesions in patients with multiple myeloma
- Corticosteroid-induced osteoporosis
- Increasing bone mass in men with osteoporosis
- Osteoporosis in postmenopausal women
- Paget’s disease of bone
- Prophylaxis of postmenopausal osteoporosis
Renal Impairment
Not recommended in patients with CrCl <30 mL/min
No dose adjustment required if CrCl >60 mL/min
Dose adjustment based on creatinine clearance:
| Creatinine Clearance | Dose |
|---|---|
| >60 mL/min | 4 mg |
| 50–60 mL/min | 3.5 mg |
| 40–49 mL/min | 3.3 mg |
| 30–39 mL/min | 3.0 mg |
Relevant Products / প্রাসঙ্গিক পণ্য
![Zoldix (5mg/100ml) IV Infusion | [For osteoporosis]](https://epharma.com.bd/storage/app/public/Wdav8PjiromUvNyAGyvpVMv2rHibQoLPpkBVm3M2.webp "Zoldix (5mg/100ml) IV Infusion | [For osteoporosis]")
✔️ Administration Guidelines
Dilute the required dose in 100 mL of calcium-free infusion solution
(0.9% sodium chloride or 5% glucose)
Infusion duration must be at least 15 minutes
Use the solution immediately after preparation; if necessary, store at 2–8°C for up to 24 hours
Allow refrigerated solutions to reach room temperature before infusion
Do not mix with calcium-containing or divalent cation solutions (e.g., Lactated Ringer’s)
Administer as a single intravenous infusion via a separate line
✔️ Dosage & Administration
Hypercalcemia of Malignancy
Recommended dose: 4 mg as a single intravenous infusion
Indicated for patients with corrected serum calcium ≥12 mg/dL (3.0 mmol/L)
No dose adjustment is required in mild to moderate renal impairment
Retreatment may be considered if calcium levels do not normalize
A minimum interval of 7 days should elapse before retreatment
Multiple Myeloma and Bone Metastases from Solid Tumors
Recommended dose: 4 mg IV infusion every 3–4 weeks
Patients should receive daily supplementation with:
Calcium 500 mg
Vitamin D 400 IU
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
✔️ Limited clinical experience exists. Overdose may result in:
- Hypocalcemia
- Hypophosphatemia
- Hypomagnesemia
- Management includes intravenous replacement with:
- Calcium gluconate
- Phosphate salts
- Magnesium sulfate, as clinically indicated
✔️ Drug Interactions
No clinically significant interactions observed with commonly used anticancer agents, antibiotics, diuretics, or analgesics
Caution required with:
Aminoglycosides (prolonged hypocalcemia risk)
Loop diuretics (increased hypocalcemia risk)
Thalidomide (increased renal dysfunction risk in multiple myeloma)
Other potentially nephrotoxic agents
✔️ Adverse Effects
Commonly reported adverse reactions include:
- Headache, fatigue, fever
- Nausea, vomiting, anorexia, constipation
- Bone pain, myalgia, arthralgia
- Flu-like syndrome
- Hypocalcemia, hypophosphatemia
- Anemia
- Osteonecrosis of the jaw
✔️ Contraindications
- Hypersensitivity to zoledronic acid, excipients, or other bisphosphonates
- Severe renal impairment (creatinine clearance <30 mL/min)
- Pregnancy and lactation
✔️ Pregnancy & Lactation
Zoledronic acid is contraindicated during pregnancy and breastfeeding.
Use is not recommended in children and adolescents below 18 years of age.
✔️ Precautions & Warnings
- Ensure adequate hydration prior to administration, especially in elderly patients and those receiving diuretics
- Patients should drink fluids before and after infusion
- Monitor serum levels of calcium, phosphate, magnesium, potassium, and serum creatinine
- Supplemental therapy may be required if electrolyte abnormalities occur
- Renal function should be monitored closely throughout treatment
✔️ Storage Conditions
Store below 30°C prior to opening
Protect from light and moisture
Keep out of reach and sight of children
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.
